10-Q: Cyanotech Reports Third Quarter and First Nine Months Fiscal 2024 Results Amidst Market Challenges

Cyanotech reported a decrease in net sales for both the third quarter and first nine months of fiscal year 2024, driven by lower bulk sales and macroeconomic pressures.

Summary

• Cyanotech's net sales decreased by 5.2% to $5.582 million for the third quarter of fiscal year 2024, compared to $5.891 million in the same period last year.
• The company's gross profit for the quarter was $1.649 million, with a gross profit margin of 29.5%, down from 29.9% in the prior year.
• Operating loss for the third quarter was $848,000, compared to a loss of $404,000 in the same period of the previous year.
• Net loss for the quarter was $1.020 million, or $0.16 per diluted share, compared to a net loss of $598,000, or $0.10 per diluted share, in the prior year.
• For the first nine months of fiscal year 2024, net sales decreased by 3.9% to $17.101 million, compared to $17.786 million in the same period last year.
• Gross profit for the first nine months was $5.270 million, with a gross profit margin of 30.8%, down from 33.0% in the prior year.
• Operating loss for the first nine months was $2.689 million, compared to a loss of $1.666 million in the same period of the previous year.
• Net loss for the first nine months was $3.186 million, or $0.50 per diluted share, compared to a net loss of $2.010 million, or $0.32 per diluted share, in the prior year.
• The company experienced lower demand in bulk sales and some impacts from timing of customer orders for astaxanthin bulk.
• The company has seen increased sales primarily due to the timing of shipments and increased demand for one of its key customers.
• The company's working capital decreased to $3.7 million as of December 31, 2023, from $5.4 million as of March 31, 2023.
• The company completed a private placement of 400,000 shares at $1.00 per share, raising $392,000 for general working capital.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to declining sales, increased losses, and liquidity concerns. The company is facing significant challenges in the market and is expected to be delisted from Nasdaq. While there are some positive notes about the company's efforts to revitalize sales and marketing, the overall tone is pessimistic.

Positives

• The company has revitalized its sales and marketing team, including the addition of a Chief Commercial Officer.
• The company is focusing on enhancing customer messaging on premium quality and competitive advantages.
• The company completed a private placement, raising $392,000 for general working capital.
• The company is emphasizing its naturally farmed microalgae from Hawaii with pristine waters and natural sourcing practices.
• The company is aligning with rising consumer objectives and growing demand for responsible, sustainable and U.S. grown products.

Negatives

• The company experienced a decrease in net sales for both the third quarter and first nine months of fiscal year 2024.
• The company's gross profit margin decreased in both the third quarter and first nine months of fiscal year 2024.
• The company's operating loss increased in both the third quarter and first nine months of fiscal year 2024.
• The company's net loss per share increased in both the third quarter and first nine months of fiscal year 2024.
• The company is facing challenges in the bulk material market due to price sensitivity and competition from international ingredients.
• The company's working capital decreased by $1.6 million from March 31, 2023 to December 31, 2023.

Risks

• The company is facing challenges due to macroeconomic conditions leading to lower sales.
• The company is experiencing increased price sensitivity in the bulk material market.
• The company's ability to continue as a going concern is in doubt due to operating losses and negative cash flows.
• The company was not in compliance with a debt covenant at March 31, 2023, and the bank froze additional advances from the credit agreement.
• The company's future results may fluctuate due to changes in sales volumes, weather patterns, increased competition, and other factors beyond its control.
• The company's production levels may be impacted by imbalances in the biological production systems, volatile energy costs, and changing world markets.
• The company's common stock is expected to be delisted from Nasdaq due to failure to comply with the minimum bid price rule.

Future Outlook

The company will focus on stabilizing production volume, rationalizing market channel participation, and leveraging core competencies. Emphasis will be placed on Nutrex Hawaiian consumer products while exploring bulk sales opportunities. The company expects extraction services to generate additional income. Gross profit margins may be impacted by lower production volumes, input costs, and competition. The company will balance production with sales demand and manage expenses judiciously. A prolonged downturn in sales could impair the company's ability to generate sufficient cash for operations.

Management Comments

• Matthew K. Custer, President and CEO, stated that the macroeconomic environment led to lower sales across the portfolio, particularly in Spirulina bulk sales.
• He noted that consumers are trading down to private label brands to save on costs.
• He mentioned the revitalization of the sales and marketing team and the focus on enhancing customer messaging on premium quality and competitive advantages.
• He highlighted the company's naturally farmed microalgae from Hawaii and its alignment with consumer demand for responsible, sustainable, and U.S. grown products.

Industry Context

The document indicates that the dietary supplement market is experiencing a shift where consumers are trading down to private label brands to save costs. The bulk material market is becoming increasingly price-sensitive, with companies sourcing lower-priced international ingredients. This suggests increased competition and pricing pressure within the industry, impacting Cyanotech's sales and margins.

Comparison to Industry Standards

• The document does not provide specific industry benchmarks for comparison.
• However, the company's struggles with declining sales and margins suggest it is underperforming compared to some competitors in the dietary supplement market.
• The company's reliance on bulk sales, which are facing price pressures, is a potential weakness compared to companies with a stronger focus on higher-margin consumer products.
• The company's challenges with debt covenants and liquidity issues are not typical for well-performing companies in the industry.
• The company's expected delisting from Nasdaq is a significant negative event, indicating a failure to meet listing requirements, which is not a common occurrence for established companies.

Related Party Transactions

• The company has a loan facility with a related party that allows it to borrow up to $2.0 million on a revolving basis.
• The company completed a private placement with its Chairman of the Board, raising $392,000.

Stakeholder Impact

• Shareholders will be negatively impacted by the declining financial performance and the expected delisting from Nasdaq.
• Employees may be affected by cost-saving measures, including reduced headcount and compensation.
• Customers may experience changes in product availability or pricing due to the company's financial challenges.
• Suppliers may face increased risk due to the company's liquidity concerns.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will focus on stabilizing production volume, rationalizing market channel participation, and leveraging core competencies.
• The company will continue to place emphasis on its Nutrex Hawaiian consumer products while exploring further opportunities for bulk sales orders.
• The company will leverage its experience and reputation for quality, nutritional products which promote health and well-being.
• The company will host a virtual broadcast on February 9, 2024, to respond to questions about its operating results.
• The company expects its common stock to be delisted from Nasdaq on February 20, 2024, and will seek to trade over-the-counter.

Key Dates

Keywords

microalgae, astaxanthin, spirulina, dietary supplements, bulk sales, private placement, financial results, operating loss, net loss, gross profit, debt, working capital